iBio
IBIO
21 hedge funds and large institutions have $345K invested in iBio in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 10 closing their positions.
9,550% more call options, than puts
Call options by funds: $193K | Put options by funds: $2K
28% more capital invested
Capital invested by funds: $270K → $345K (+$74.7K)
17.67% more ownership
Funds ownership: 0.16% → 17.83% (+18%)
19% less funds holding
Funds holding: 26 → 21 (-5)
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$772K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$111K |
| 3 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$83K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$74.1K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$20.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$76.2K |
| 2 |
APP
Avantax Planning Partners
Dubuque,
Iowa
|
-$47K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$34.2K |
| 4 |
HF
HRT Financial
New York
|
-$19K |
| 5 |
State Street
Boston,
Massachusetts
|
-$14.6K |
IBIO Hedge Fund Activity: Q4 2023 in Review
21 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in iBio (IBIO) for Q4 2023, worth a combined $345K — up 28% from $270K a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of IBIO and 5 opened new positions — a net loss of 5 holders — while 8 trimmed existing stakes and 5 added.
The largest buyer was Sabby Management, opening a new position worth an estimated $772K. The largest seller was Vanguard Group, exiting entirely with an estimated $76.2K sold.
- 21 institutional investors held iBio (IBIO) as of Q4 2023, down from 26 in Q3 2023.
- Funds reported $345K of iBio stock for Q4 2023, up 28% quarter-over-quarter.
- 5 funds opened new iBio positions in Q4 2023 and 10 closed out, a net change of -5 holders.
- The largest iBio buyer in Q4 2023 was Sabby Management, an estimated $772K added.
- The largest iBio seller in Q4 2023 was Vanguard Group, an estimated $76.2K sold.
Based on aggregated 13F filings for Q4 2023.